MedTrace Logo

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

NCT07208773 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2025-11-17

No results posted yet for this study

Summary

This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.

Conditions

Interventions

DRUG

YL201

YL201 will be administered as IV infusion

DRUG

Ivonescimab

Ivonescimab will be administered as IV infusion.

Sponsors & Collaborators

  • Akesobio

    collaborator INDUSTRY

  • MediLink Therapeutics (Suzhou) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-29
Primary Completion
2027-01-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07208773 on ClinicalTrials.gov